RAPP SEC Filing News — Rapport Therapeutics, Inc.

Latest SEC filings for Rapport Therapeutics, Inc. (RAPP) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-10-08.

Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, includi…
Sector: Healthcare Industry: Biotechnology Market Cap: $1.4B CIK: 2012593
20
Total Filings
0
Bullish Classifications
12
Bearish Classifications
12
Insider Transactions
1
Material Events (8-K)
1
Periodic Reports
Rule-based classifications for RAPP currently lean bearish. Of the 20 filing records displayed, 12 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 0 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.
RAPP Filing Activity Snapshot 2026-06-30 — 2026-10-08
Insider Transactions (Form 4)
0 buys vs 12 sells
Net insider selling in this period — insiders sell for many reasons beyond conviction.
Largest Form 144 Filing
$2.53M
Yeleswaram Krishnaswamy (Chief Development Officer) · 2026-08-26
50,160 shares · Form 4
Form 144 Notices
6
Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.
Insider Transactions 12 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 12 filings in this group are Form 4s for Rapport Therapeutics, Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 12 insider filings shown, the breakdown is 12 open-market sale. 12 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Open-market sale ×12
The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.
Form 4 Open-market sale Insider Selling 2026-10-08

RAPP insider Ceesay Abraham (Director, Chief Executive Officer) sold 4,522 shares (~$143.3K)

Ceesay Abraham, listed as Director, Chief Executive Officer at Rapport Therapeutics, Inc., reported an open-market sale of 4,522 RAPP shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 3,375 $32.03 $108.1K
S Open-market sale 1,147 $30.66 $35.2K
Filing: Form 4 (Insider Transaction) Insider: Ceesay Abraham (Director, Chief Executive Officer) Shares: 4,522 Est. Value: $143.3K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-10-01

RAPP insider Gault Cheryl (Chief Operating Officer) sold 10,000 shares (~$331.9K)

Gault Cheryl, listed as Chief Operating Officer at Rapport Therapeutics, Inc., reported an open-market sale of 10,000 RAPP shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 7,925 $33.04 $261.8K
S Open-market sale 2,075 $33.76 $70.0K
Filing: Form 4 (Insider Transaction) Insider: Gault Cheryl (Chief Operating Officer) Shares: 10,000 Est. Value: $331.9K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-09-24

RAPP insider Ceesay Abraham (Director, Chief Executive Officer) sold 2,210 shares (~$86.6K)

Ceesay Abraham, listed as Director, Chief Executive Officer at Rapport Therapeutics, Inc., reported an open-market sale of 2,210 RAPP shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 1,952 $39.05 $76.2K
S Open-market sale 215 $39.86 $8.6K
S Open-market sale 43 $41.05 $1.8K
Filing: Form 4 (Insider Transaction) Insider: Ceesay Abraham (Director, Chief Executive Officer) Shares: 2,210 Est. Value: $86.6K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-09-09

RAPP insider Ceesay Abraham (Director, Chief Executive Officer) sold 8,210 shares (~$374.5K)

Ceesay Abraham, listed as Director, Chief Executive Officer at Rapport Therapeutics, Inc., reported an open-market sale of 8,210 RAPP shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 7,141 $45.55 $325.3K
S Open-market sale 1,069 $46.01 $49.2K
Filing: Form 4 (Insider Transaction) Insider: Ceesay Abraham (Director, Chief Executive Officer) Shares: 8,210 Est. Value: $374.5K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-26

RAPP insider Ceesay Abraham (Director, Chief Executive Officer) sold 18,921 shares (~$938.0K)

Ceesay Abraham, listed as Director, Chief Executive Officer at Rapport Therapeutics, Inc., reported an open-market sale of 18,921 RAPP shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 18,921 $49.57 $938.0K
Filing: Form 4 (Insider Transaction) Insider: Ceesay Abraham (Director, Chief Executive Officer) Shares: 18,921 Est. Value: $938.0K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-26

RAPP insider Yeleswaram Krishnaswamy (Chief Development Officer) sold 50,160 shares (~$2.53M)

Yeleswaram Krishnaswamy, listed as Chief Development Officer at Rapport Therapeutics, Inc., reported an open-market sale of 50,160 RAPP shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 13,160 $50.00 $658.0K
S Open-market sale 20,799 $50.31 $1.05M
S Open-market sale 16,201 $51.06 $827.2K
Filing: Form 4 (Insider Transaction) Insider: Yeleswaram Krishnaswamy (Chief Development Officer) Shares: 50,160 Est. Value: $2.53M
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-20

RAPP insider Yeleswaram Krishnaswamy (Chief Development Officer) sold 404 shares (~$20.2K)

Yeleswaram Krishnaswamy, listed as Chief Development Officer at Rapport Therapeutics, Inc., reported an open-market sale of 404 RAPP shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 404 $49.90 $20.2K
Filing: Form 4 (Insider Transaction) Insider: Yeleswaram Krishnaswamy (Chief Development Officer) Shares: 404 Est. Value: $20.2K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-12

RAPP insider Ceesay Abraham (Director, Chief Executive Officer) sold 51,499 shares (~$2.43M)

Ceesay Abraham, listed as Director, Chief Executive Officer at Rapport Therapeutics, Inc., reported an open-market sale of 51,499 RAPP shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 14,171 $45.97 $651.5K
S Open-market sale 8,370 $46.75 $391.3K
S Open-market sale 3,664 $46.90 $171.8K
S Open-market sale 19,500 $48.04 $936.8K
S Open-market sale 5,794 $48.62 $281.7K
Filing: Form 4 (Insider Transaction) Insider: Ceesay Abraham (Director, Chief Executive Officer) Shares: 51,499 Est. Value: $2.43M
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-07-29

RAPP insider Ceesay Abraham (Director, Chief Executive Officer) sold 2,210 shares (~$93.1K)

Ceesay Abraham, listed as Director, Chief Executive Officer at Rapport Therapeutics, Inc., reported an open-market sale of 2,210 RAPP shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 2,203 $42.11 $92.8K
S Open-market sale 7 $42.73 $299.14
Filing: Form 4 (Insider Transaction) Insider: Ceesay Abraham (Director, Chief Executive Officer) Shares: 2,210 Est. Value: $93.1K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-07-15

RAPP insider Ceesay Abraham (Director, Chief Executive Officer) sold 8,210 shares (~$328.4K)

Ceesay Abraham, listed as Director, Chief Executive Officer at Rapport Therapeutics, Inc., reported an open-market sale of 8,210 RAPP shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 5,481 $39.72 $217.7K
S Open-market sale 2,729 $40.57 $110.7K
Filing: Form 4 (Insider Transaction) Insider: Ceesay Abraham (Director, Chief Executive Officer) Shares: 8,210 Est. Value: $328.4K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-07-01

RAPP insider Gault Cheryl (Chief Operating Officer) sold 10,000 shares (~$415.8K)

Gault Cheryl, listed as Chief Operating Officer at Rapport Therapeutics, Inc., reported an open-market sale of 10,000 RAPP shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 1,900 $40.09 $76.2K
S Open-market sale 3,792 $41.39 $157.0K
S Open-market sale 3,308 $42.17 $139.5K
S Open-market sale 1,000 $43.15 $43.2K
Filing: Form 4 (Insider Transaction) Insider: Gault Cheryl (Chief Operating Officer) Shares: 10,000 Est. Value: $415.8K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-07-01

RAPP insider Ceesay Abraham (Director, Chief Executive Officer) sold 8,220 shares (~$327.4K)

Ceesay Abraham, listed as Director, Chief Executive Officer at Rapport Therapeutics, Inc., reported an open-market sale of 8,220 RAPP shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 7,344 $39.77 $292.1K
S Open-market sale 876 $40.34 $35.3K
Filing: Form 4 (Insider Transaction) Insider: Ceesay Abraham (Director, Chief Executive Officer) Shares: 8,220 Est. Value: $327.4K
View on SEC EDGAR → Open Filing Document →
Proposed Insider Sales 6 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. Rapport Therapeutics, Inc. has 6 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-10-06

RAPP Form 144 filed for proposed insider sale by Abraham N. Ceesay (39,470 shares) ~$1.23M

Abraham N. Ceesay filed a Form 144 with the SEC indicating intent to sell RAPP (Rapport Therapeutics, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Abraham N. Ceesay Shares: 39,470 Est. Value: $1.23M
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-09-30

RAPP Form 144 filed for proposed insider sale by CHERYL GAULT (10,000 shares) ~$330.2K

CHERYL GAULT filed a Form 144 with the SEC indicating intent to sell RAPP (Rapport Therapeutics, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: CHERYL GAULT Shares: 10,000 Est. Value: $330.2K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-08-25

RAPP Form 144 filed for proposed insider sale by KRISHNASWAMY YELESWARAM (37,000 shares) ~$1.83M

KRISHNASWAMY YELESWARAM filed a Form 144 with the SEC indicating intent to sell RAPP (Rapport Therapeutics, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: KRISHNASWAMY YELESWARAM Shares: 37,000 Est. Value: $1.83M
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-08-24

RAPP Form 144 filed for proposed insider sale by KRISHNASWAMY YELESWARAM (11,472 shares) ~$553.4K

KRISHNASWAMY YELESWARAM filed a Form 144 with the SEC indicating intent to sell RAPP (Rapport Therapeutics, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: KRISHNASWAMY YELESWARAM Shares: 11,472 Est. Value: $553.4K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-08-19

RAPP Form 144 filed for proposed insider sale by KRISHNASWAMY YELESWARAM (2,092 shares) ~$102.5K

KRISHNASWAMY YELESWARAM filed a Form 144 with the SEC indicating intent to sell RAPP (Rapport Therapeutics, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: KRISHNASWAMY YELESWARAM Shares: 2,092 Est. Value: $102.5K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-06-30

RAPP Form 144 filed for proposed insider sale by CHERYL GAULT (10,000 shares) ~$403.9K

CHERYL GAULT filed a Form 144 with the SEC indicating intent to sell RAPP (Rapport Therapeutics, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: CHERYL GAULT Shares: 10,000 Est. Value: $403.9K
View on SEC EDGAR → Open Filing Document →
Material Events 1 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There is 1 in this period for Rapport Therapeutics, Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-08-05

RAPP filed 8-K — material company event

Rapport Therapeutics, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Periodic Reports 1 · Forms 10-K and 10-Q

The periodic reports are where the audited and reviewed financial statements live. This period contains 1 quarterly report (10-Q) for Rapport Therapeutics, Inc.

The two are not equivalent in weight. A 10-K is audited by an external firm and includes the full risk factor disclosure, business description and management discussion; a 10-Q is unaudited, reviewed rather than examined, and much shorter. When a figure in a quarterly report is later revised, the annual report is usually where the correction appears.

An amended report — 10-K/A or 10-Q/A — restates or corrects something in the original filing, and is worth reading against the version it replaces.

Form 10-Q Quarterly Report 2026-08-05

RAPP filed Quarterly Report (10-Q)

Rapport Therapeutics, Inc. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)
View on SEC EDGAR → Open Filing Document →

How we classify Rapport Therapeutics, Inc.'s filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on RAPP. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — RAPP SEC Filings

More Tools for RAPP

RAPP Full Stock Analysis RAPP Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper RAPP analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the RAPP stock analysis page.

RAPP Full Analysis
Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.
Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer